Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.39 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5382942 | 0.95 | METTL3 (0.43) | NR1H4PARP1METTL3METTL14CHRNB2 | |
| SCHEMBL7385487 | 0.79 | PARP1 (0.41) | PARP1AOC3MAOB | |
| SCHEMBL3640169 | 0.75 | AOC3 (0.44) | AOC3 | |
| SCHEMBL1465455 | 0.75 | CYP2A6 (0.42) | PARP1METTL3METTL14CHRNB2CHRNA7 | |
| SCHEMBL73543 | 0.74 | AOC3 (0.47) | CHRNA7AOC3MAOB | |
| SCHEMBL2467564 | 0.74 | HTR2A (0.49) | PARP1 | |
| SCHEMBL10441226 | 0.74 | AOC3 (0.42) | AOC3 | |
| SCHEMBL28595175 | 0.73 | CYP19A1 (0.41) | — | |
| SCHEMBL1237690 | 0.72 | MAOB (0.49) | AOC3MAOB | |
| SCHEMBL29688552 | 0.72 | MAOB (0.49) | AOC3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7271192-B2 | Substituted 2-pyrrolidine-2-yl-1H-indole compounds | GRUENENTHAL GMBH (DE) | 2007-09-18 | — | — | US | claimed |
| EP-1451177-B1 | SUBSTITUTED 2-PYRROLIDINE-2-YL-1H-INDOLE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | GRUENENTHAL GMBH (DE) | 2007-03-21 | — | — | EP | claimed |
| US-20050014815-A1 | Substituted 2-pyrrolidine-2-yl-1H-indole compounds | GRUENENTHAL GMBH (DE) | 2005-01-20 | — | — | US | claimed |
| US-20240124404-A1 | COMPOSITION FOR TREATING DISEASES RELATED TO ADVANCED GLYCATION END PRODUCTS COMPRISING INDOLE DERIVATIVE | METACEN THERAPEUTICS (KR) | 2024-04-18 | — | — | US | disclosed |
| EP-4353227-A1 | COMPOSITION INCLUDING INDOLE DERIVATIVE FOR PREVENTION OF ADVANCED GLYCATION END PRODUCT-RELATED DISEASE | Metacen Therapeutics (KR) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022260492-A1 | COMPOSITION INCLUDING INDOLE DERIVATIVE FOR PREVENTION OF ADVANCED GLYCATION END PRODUCT-RELATED DISEASE | 주식회사 메타센테라퓨틱스 | 2022-12-15 | — | — | WO | disclosed |
| US-8669266-B2 | Quinoline-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2014-03-11 | — | — | US | disclosed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| US-7273882-B2 | Aminoacetamide acyl guanidines as β-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-25 | — | — | US | disclosed |
| US-7273882-B2 | Aminoacetamide acyl guanidines as β-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-25 | — | — | US | disclosed |
| US-7271192-B2 | Substituted 2-pyrrolidine-2-yl-1H-indole compounds | GRUENENTHAL GMBH (DE) | 2007-09-18 | — | — | US | disclosed |
| US-7271192-B2 | Substituted 2-pyrrolidine-2-yl-1H-indole compounds | GRUENENTHAL GMBH (DE) | 2007-09-18 | — | — | US | disclosed |
| US-7271192-B2 | Substituted 2-pyrrolidine-2-yl-1H-indole compounds | GRUENENTHAL GMBH (DE) | 2007-09-18 | — | — | US | disclosed |
| EP-1451177-B1 | SUBSTITUTED 2-PYRROLIDINE-2-YL-1H-INDOLE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | GRUENENTHAL GMBH (DE) | 2007-03-21 | — | — | EP | disclosed |
| WO-2007002220-A2 | AMINOACETAMIDE ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20050014815-A1 | Substituted 2-pyrrolidine-2-yl-1H-indole compounds | GRUENENTHAL GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| US-20050014815-A1 | Substituted 2-pyrrolidine-2-yl-1H-indole compounds | GRUENENTHAL GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| US-20050014815-A1 | Substituted 2-pyrrolidine-2-yl-1H-indole compounds | GRUENENTHAL GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| EP-1451177-A1 | SUBSTITUTED 2-PYRROLIDINE-2-YL-1H-INDOLE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | Grünenthal GmbH (DE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003048156-A1 | SUBSTITUTED 2-PYRROLIDINE-2-YL-1H-INDOLE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | Grünenthal GmbH (DE) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY1, P2RY2 | NR1H4 1961/4885CHRM5 54/4885CHRM3 88/4885 |
| US-20240124404-A1 | COMPOSITION FOR TREATING DISEASES RELATED TO ADVANCED GLYCATION END PRODUCTS COMPRISING INDOLE DERIVATIVE | AGER, IDO1, IAPP | NR1H4 4382/4885CHRM5 623/4885CHRM3 571/4885 |
| US-20050014815-A1 | Substituted 2-pyrrolidine-2-yl-1H-indole compounds | IDO1, IDO2, TPH2 | NR1H4 3805/4885CHRM5 675/4885CHRM3 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.